New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyond

Lung cancer is the leading cause of mortality worldwide. Non-small cell lung cancer (NSCLC) is a particularly aggressive cancer, the optimum management of which is still being determined. In the metastatic disease, the standard therapy is a platinum-based combination chemotherapy; however, in spite...

Descripción completa

Detalles Bibliográficos
Autores principales: Gori, Bruno, Ricciardi, Serena, Fulvi, Alberto, Intagliata, Salvatore, Signore, Ester Del, de Marinis, Filippo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3253753/
https://www.ncbi.nlm.nih.gov/pubmed/22241943
http://dx.doi.org/10.2147/TCRM.S22079

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3253753/
https://www.ncbi.nlm.nih.gov/pubmed/22241943
http://dx.doi.org/10.2147/TCRM.S22079

Ejemplares similares